Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06930573 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 16, 2025 (before its estimated May 24, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This study is a single-arm, open-label study. To assess the efficacy and safety of AK112 therapy in patients with resectable hepatocellular carcinoma at high risk of recurrence. The primary endpoint is the 12-month RFS rate of resectable hepatocellular carcinoma.
Trial Details
NCT Number NCT06930573
Lead Sponsor The First Affiliated Hospital of Zhengzhou University
Conditions
(from sponsor)		 HCC
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov